Introduction
============

Malnutrition is one of the most common comorbidities in patients with chronic obstructive pulmonary disease (COPD), and is also an independent risk factor for death in these patients.[@b1-copd-9-863],[@b2-copd-9-863] In addition to excessive energy expenditure on exertive breath and the inflammatory response,[@b3-copd-9-863] patients with COPD, especially those with acute exacerbations, usually have a worse appetite and ingest less food. Appetite is known to be regulated by a fine balance between orexigenic and anorexigenic neuropeptides in the hypothalamus. Among these peptides, neuropeptide Y and agouti-related peptide are potent orexigenic peptides, and are released by neuropeptide Y/agouti-related peptide neurons.[@b4-copd-9-863] On the surface of these neurons, abundant G-protein coupled receptors, so-called growth hormone secretagogue receptors, are present to mediate growth hormone secretion in the pituitary gland.[@b5-copd-9-863]

Ghrelin is an endogenous ligand of the growth hormone secretagogue receptor, secreted primarily in the stomach and secondarily in the other portions of the digestive tract.[@b6-copd-9-863] Ghrelin and another 23-amino acid peptide, obestatin, are derived from the 99-amino acid precursor, proghrelin.[@b7-copd-9-863] The active form of ghrelin has a unique modification of an octancyl group on Ser3, and accounts for 10%--40% of total ghrelin.[@b8-copd-9-863]--[@b11-copd-9-863] The acylation modification provides large hydrophobic groups, which are essential for activation of the growth hormone secretagogue receptor. The wide distribution of growth hormone secretagogue receptors suggests a variety of physiological roles for acylated (acyl) ghrelin, including stimulation of appetite, regulation of glucose metabolism, and long-term regulation of energy balance.[@b12-copd-9-863] These functions are regulated by circulating levels of acyl ghrelin.

Itoh et al first studied ghrelin in COPD because of the close association between ghrelin and nutritional status, and reported an elevated plasma ghrelin level in underweight patients.[@b13-copd-9-863] Thereafter, several studies compared the plasma ghrelin level in stable COPD patients and healthy controls, but inconsistent results were reported.[@b14-copd-9-863]--[@b17-copd-9-863] These works focused on the association of ghrelin level with body mass index, inflammatory markers, and other related peptides, but none measured acyl ghrelin level or assessed appetite. Although Nagaya et al showed that ghrelin effectively treated underweight COPD patients,[@b18-copd-9-863] whether the reduction of appetite was associated with a lower plasma ghrelin level in COPD is unclear.

A very poor appetite is observed in many patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD), and these patients usually have complications of gastric mucosal injury and gastrointestinal disorders, particularly those with a severe inflammatory response, hypoxia, or hypercapnia. Until now, limited studies have examined circulating levels of acyl ghrelin in patients with AECOPD. This study aimed to measure circulating levels of total and acyl ghrelin in AECOPD, and evaluated patients' appetite and caloric intake, in order to explore the possible relationship between ghrelin secretion, acylation, and appetite regulation in patients with AECOPD.

Materials and methods
=====================

This study was approved by the institutional review board of Sichuan University (approval number ChiCTR-OCS-12001888). Informed consent was obtained from all subjects.

Study subjects
--------------

Thirty-six consecutive patients with AECOPD admitted to West China Hospital, Sichuan University, Chengdu, People's Republic of China, were enrolled in this study. COPD and AECOPD were diagnosed based on 2013 GOLD (Global Initiative for Chronic Obstructive Lung Disease) criteria. Patients with diabetes, hypertension, gastritis, or pulmonary encephalopathy were excluded due to possible interference with appetite assessment and ghrelin measurement. An age-matched subset of 23 healthy adults was recruited as the control.

All the patients were previously diagnosed with COPD in outpatient care or during a previous hospitalization, and had recent pulmonary function test results (within 6 months). Forced vital capacity and forced expiratory volume in one second (FEV~1~) were measured by standard spirometric techniques (MasterScreen™ spirometer; CareFusion Germany 234 GmbH, Höchberg, Germany), using the reference values proposed by Zheng and Zhong.[@b19-copd-9-863] GOLD stage was determined by the patient's lung function data. The height and weight of each patient was measured at discharge to avoid deviations in the status of acute exacerbation.

Study design
------------

Total ghrelin, acyl ghrelin, and obestatin levels were recorded, along with evaluation of appetite and caloric intake, at both admission and discharge in the patients with AECOPD. The Simplified Nutritional Appetite Questionnaire (SNAQ)[@b20-copd-9-863] was used to evaluate appetite in all subjects, and caloric intake was measured with reference to the China Food Composition for the calorie count of each type of food.[@b21-copd-9-863] These parameters were also compared between healthy controls and patients with AECOPD at admission.

For each patient with AECOPD, two blood samples were taken, one in the first 24 hours after admission to hospital and the other on the day before discharge. Blood was taken from the antecubital vein at around 7 am after an overnight fast. Administration of glucocorticoids, glucose, and intravenous nutrition was avoided in the 24 hours before blood sampling. The samples were processed as quickly as possible to avoid breakdown of peptides, and then centrifuged at 4°C and stored at −80°C until analysis. Plasma levels of total ghrelin, acylated ghrelin, and obestatin were measured using radioimmunoassay kits (Millipore, Billerica, MA, USA) following the manufacturer's instructions. Peptide measurements and appetite assessments were not performed in 13 patients with AECOPD at discharge (two who died, four who were intubated, and seven who were discharged ahead of time). C-reactive protein and interleukin-6 were measured by the Department of Laboratory Medicine, West China Hospital, with immunoturbidimetric assays at admission and at discharge. These measurements were also performed in controls.

Statistical analysis
--------------------

The data were expressed as the mean ± standard deviation (normal distribution) or the median (interquartile range; skewed distribution). The parameters were compared between the acute exacerbation and the remission phase of COPD using the paired Student's *t*-test (for differences with normal distribution) or the Wilcoxon signed-rank test (for differences with skewed distribution). Comparisons of parameters between patients and controls were made using the two independent samples Student's *t*-test or the Wilcoxon rank-sum test. Correlations between plasma ghrelin and pulmonary function parameters were examined by Pearson correlation or Spearman correlation analysis. *P*\<0.05 was considered to be statistically significant.

Results
=======

Patient characteristics
-----------------------

As shown in [Table 1](#t1-copd-9-863){ref-type="table"}, there were 27 males and nine females in the AECOPD group, and 15 males and eight females in the control group. No significant differences in age or sex were observed between patients and controls at admission. The body mass index of the patients was significantly less than that of controls. Sixteen healthy controls and 22 patients with AECOPD were smokers, and there was no significant difference in pulmonary function (FEV~1~ %, forced vital capacity), C-reactive protein, interleukin-6, pressure of oxygen (pO~2~) or pressure of carbon dioxide (pCO~2~) between smokers and nonsmokers with AECOPD. Pulmonary function tests were significantly worse in patients with AECOPD than in healthy controls, with much lower FEV~1~ (and FEV~1~%) values. The numbers of patients in each COPD stage were GOLD 1 (n=0), GOLD 2 (n=4), GOLD 3 (n=16), and GOLD 4 (n=16).

The mean duration of COPD was 14.2 years. All patients had received antibiotic therapies. Thirty-four patients had been treated with inhaled glucocorticoids, 12 with intravenous glucocorticoids, and 14 with inhaled anticholinergics. The mean length of stay in hospital was 11.7 days. Seventeen patients also had pulmonary heart disease, diagnosed according to evidence of pulmonary hypertension, right heart insufficiency, and/or enlargement of the right heart ventricle.

Circulating levels of blood cells and biochemical indices
---------------------------------------------------------

Blood cell counts, biochemical indices, and inflammatory markers for all subjects are shown in [Table 2](#t2-copd-9-863){ref-type="table"}. Compared with healthy controls, patients with AECOPD at the peak of their exacerbation (on admission) had significantly higher white blood cell counts, percentage of neutrophils, pCO~2~, HCO~3~, C-reactive protein, interleukin-6, and glucose levels, and significantly lower hemoglobin, protein, and albumin levels. Twenty-eight patients with AECOPD received low-flow oxygen therapy, so the difference in pO~2~ between patients and controls was not statistically significant.

In the 23 patients with AECOPD who underwent two blood sampling collections, there was no significant difference in blood cell count, pO~2~ level, or pH value between the two measurement points (at admission and discharge). When compared with values at admission, pCO~2~, protein, albumin, C-reactive protein, and interleukin-6 levels were significantly lower at discharge.

Evaluation of appetite and caloric intake
-----------------------------------------

Appetite, evaluated by SNAQ score, was significantly worse in patients with AECOPD at admission than in healthy controls. Patients with AECOPD at the peak of their exacerbation had a much lower daily calorie intake than healthy controls ([Figure 1](#f1-copd-9-863){ref-type="fig"}). After treatment, SNAQ scores and calorie intake in patients with AECOPD were both increased at discharge ([Figure 2](#f2-copd-9-863){ref-type="fig"}).

Circulating levels of ghrelin and related peptides
--------------------------------------------------

On admission, circulating levels of acyl ghrelin were not significantly different between patients with AECOPD and healthy controls, and there were no significant differences in total ghrelin or obestatin levels. However, the acyl to total ghrelin ratio was significantly lower in patients with AECOPD when compared with healthy controls ([Figure 3](#f3-copd-9-863){ref-type="fig"}).

Patients at the peak of exacerbation (on admission) had significantly higher circulating total ghrelin levels than at discharge. Obestatin levels were also higher at admission. There was no significant difference in the acyl to total ghrelin ratio between admission and discharge ([Figure 4](#f4-copd-9-863){ref-type="fig"}).

In patients with AECOPD, the ghrelin level at admission was negatively correlated with FEV~1~ % (*r*= −0.537, *P*=0.008). Correlations between total ghrelin level and body mass index as well as inflammatory cytokines were not significant. In addition, there was no significant difference in circulating levels of ghrelin or other related peptides between smokers and nonsmokers, or between patients with and without respiratory failure. Notably, the difference in albumin level between patients at discharge and on admission was positively correlated with the total ghrelin level ([Figure 5](#f5-copd-9-863){ref-type="fig"}).

Discussion
==========

In the present study, we demonstrated that patients with AECOPD had a significantly worse appetite, a lower calorie intake, and a lower acyl to total ghrelin ratio than controls, but the differences in acyl ghrelin and total ghrelin levels were not statistically significant. In addition, we found that SNAQ scores and caloric intake in patients with AECOPD were significantly increased, while the total ghrelin level was decreased at discharge after treatment. There was no significant difference in the acyl ghrelin to total ghrelin ratio between admission and discharge. Further, we found that the circulating level of ghrelin at admission was positively correlated with the differences in albumin levels during hospitalization, but was negatively correlated with FEV~1~.

To test our hypothesis that decreased appetite in AECOPD is caused by a lower circulating level of acyl ghrelin, we compared patients with AECOPD and healthy controls. The appetite score and caloric intake were both significantly lower in patients with AECOPD than in healthy controls, but we did not find a significantly lower circulating level of acyl ghrelin in these patients. Moreover, we observed a significantly smaller appetite in patients at the peak of their exacerbation, but the change in acyl ghrelin level was not consistent with change in appetite in most patients. Therefore, we cannot conclude that the decreased appetite is caused mainly by a lower acyl ghrelin level.

Compared with healthy controls, the difference in total ghrelin level was not significant in patients with AECOPD at admission. This finding may be due to the small sample size in our study. Another explanation is that many factors can inhibit the secretion of ghrelin. For example, patients with a severe inflammatory response, hypoxia, or hypercapnia usually have complications of gastric mucosal injury and gastrointestinal disorders, so secretion and acylation of ghrelin in the stomach is vulnerable in AECOPD. On the other hand, catabolism and low caloric intake in patients with AECOPD could upregulate the secretion of ghrelin as a compensation mechanism.[@b22-copd-9-863] All these factors affect the circulating ghrelin level. However, for patients with AECOPD, the total ghrelin level at the peak of exacerbation was significantly higher than that at discharge, indicating that the compensation mechanism is a more dominant factor in stimulating ghrelin secretion.

The ratio of acyl ghrelin to total ghrelin was significantly lower in patients with AECOPD at admission than in healthy controls. This finding suggests that the acylation ratio of ghrelin in patients with AECOPD was probably less than the normal value. As explained above, production of acyl ghrelin, including secretion and acylation, occurs primarily in the stomach. Because mucosal injury and impaired stomach function are common complications in AECOPD, especially in those with a severe systemic inflammatory response and respiratory failure, the activity of ghrelin-O-acyltransferase,[@b23-copd-9-863] an enzyme that catalyzes ghrelin acylation, is probably less than that under normal conditions. Measuring the acyl ghrelin level and the activity of ghrelin-O-acyltransferase by endoscopic biopsy is a more direct and accurate method, but patients rarely consented to gastroscopy during an exacerbation. Another possible reason for a lower acyl to total ghrelin ratio in patients with AECOPD is that the breakdown of acyl ghrelin might be more rapid in the inflammation exacerbations, but further studies are needed to provide more evidence of this.

The appetite is regulated not only by orexigenic peptides, such as ghrelin, but also by anorexigenic peptides, such as lysates of pro-opiomelanocortin precursor protein, ie, melanocyte-stimulating hormone. The melanocortin system is a key site for the action of ghrelin, where agouti-related peptide competitively inhibits activation of melanocyte-stimulating hormone on downstream neurons that express melanocortin-4 receptors. It has been reported that the systemic inflammatory response increases the activity of neurons expressing pro-opiomelanocortin and release of melanocyte-stimulating hormone, resulting in decreased appetite and increased degradation of nutrients or tissue. Based on the currently available evidence, the correlations of ghrelin and acetylated ghrelin with the food questionnaire scores and caloric intake remain unclear; and regulation of appetite probably depends on a fine balance of orexigenic and anorexigenic neuropeptides in the hypothalamus. Further studies are needed to investigate this.

In this study, we found that the circulating level of albumin was decreased after treatment in patients with AECOPD. Interestingly, the circulating level of ghrelin was positively correlated with that of albumin, suggesting the possible positive regulation of ghrelin on nitrogen balance. A recent study has reported the role of des-acyl ghrelin in glucose metabolism and adiposity.[@b24-copd-9-863] Miki et al reported that ghrelin intervention achieved improvements in symptoms and ventilatory/cardiac parameters in cachectic patients with COPD, suggesting a potential role of ghrelin in the treatment of COPD.[@b25-copd-9-863] However, further studies are required to investigate whether acyl ghrelin or des-acyl ghrelin participates in protein metabolism and is of benefit in patients.

Conclusion
==========

In summary, we demonstrated lower appetite scores and caloric intake in patients with AECOPD, but could not confirm that these effects were caused by insufficient levels of the orexigenic peptide, acyl ghrelin. The reasons for the appetite reduction and the factors associated with acyl ghrelin are multifactorial. Larger, more detailed studies are needed to confirm our findings and determine the mechanism regulating appetite in patients with AECOPD.

This study was supported in part by grants (81300032, 31171103, and 81230001) from the National Natural Science Foundation of China, and a grant (2013SZ0001) from the Projects in the Science and Technology Pillar Program, Department of Science and Technology of Sichuan Province. The authors would like to thank Deying Kang and Shihong Zhou (West China School of Public Health, Sichuan University, Chengdu, People's Republic of China) for help with the statistical analysis.

**Disclosure**

The authors report no conflicts of interest in this work.

![Caloric intake and SNAQ score in patients with AECOPD and healthy controls.\
**Notes:** The SNAQ score was significantly lower in patients with AECOPD than in healthy controls (*P*\<0.001). Patients with AECOPD had a lower calorie intake in 1 day than healthy controls (*P*\<0.001, 95% confidence interval −721.8, −499.3).\
**Abbreviations:** AECOPD, acute exacerbation of chronic obstructive pulmonary disease; SNAQ, Simplified Nutritional Appetite Questionnaire.](copd-9-863Fig1){#f1-copd-9-863}

![Caloric intake and SNAQ score in patients with AECOPD at admission and on discharge.\
**Notes:** Patients with AECOPD at admission had significantly lower SNAQ scores (*P*\<0.001, 95% confidence interval −4.2, −2.8) and had a lower calorie intake (*P*\<0.001, 95% confidence interval −429.8, −306.1) than when evaluated at discharge.\
**Abbreviations:** AECOPD, acute exacerbation of chronic obstructive pulmonary disease; SNAQ, Simplified Nutritional Appetite Questionnaire.](copd-9-863Fig2){#f2-copd-9-863}

![Acyl ghrelin, total ghrelin, obestatin, and acyl to total ghrelin ratios in patients with AECOPD and healthy controls.\
**Notes:** The circulating level of acyl ghrelin was not significantly different between patients with AECOPD and healthy controls (66.81±42.88 pg/mL versus 81.30±33.31 pg/mL, *P*=0.327, 95% confidence interval −30.7, 10.4). In addition, there was no significant difference in levels of total ghrelin (623.61±196.24 pg/mL versus 556.83±186.21 pg/mL, *P*=0.199, 95% confidence interval −36.1, 169.6) or obestatin (402.04±139.94 pg/mL versus 384.88±133.04 pg/mL, *P*=0.478). The acyl to total ghrelin ratio was significantly lower in patients with AECOPD than in healthy controls (*P*=0.003).\
**Abbreviation:** AECOPD, acute exacerbation of chronic obstructive pulmonary disease.](copd-9-863Fig3){#f3-copd-9-863}

![Acyl ghrelin, total ghrelin, obestatin, and acyl to total ghrelin ratio in patients with AECOPD at admission and on discharge.\
**Notes:** Patients with AECOPD had a significantly higher circulating level of total ghrelin at admission than on discharge (627.20±234.86 pg/mL versus 500.82±181.01 pg/mL, *P*=0.001, 95% CI 59.3, 193.4). The obestatin level was higher at admission than on discharge (410.05±152.35 pg/mL versus 354.94±127.80 pg/mL, *P*=0.063, 95% CI −3.2, 113.4). In addition, there were no significant differences in the acyl ghrelin level (67.77±50.29 pg/mL versus 71.24±70.05 pg/mL, *P*=0.778, 95% CI −21.8, 28.7) or acyl to total ghrelin ratio (*P*=0.290, 95% CI −0.03, 0.30).\
**Abbreviations:** AECOPD, acute exacerbation of chronic obstructive pulmonary disease; CI, confidence interval.](copd-9-863Fig4){#f4-copd-9-863}

![Difference in albumin level in patients with AECOPD at admission and on discharge versus total ghrelin level.\
**Note:** The difference in albumin level in patients with an AECOPD at discharge and on admission was positively correlated with total ghrelin level (*r*=0.457, *P*=0.028).\
**Abbreviation:** AECOPD, acute exacerbation of chronic obstructive pulmonary disease.](copd-9-863Fig5){#f5-copd-9-863}

###### 

Patient characteristics

                                           Controls (n=23)                                       AECOPD (n=36)
  ---------------------------------------- ----------------------------------------------------- ---------------------------------------------------------------------------------------------------
  Age, years                               66.9±6.7                                              65.6±7.6[a](#tfn1-copd-9-863){ref-type="table-fn"}
  Sex, male/female                         15/8                                                  27/9
  Body mass index, kg/m^2^                 22.39±3.51                                            20.5±2.98[†](#tfn3-copd-9-863){ref-type="table-fn"}
  Smoking history                                                                                
   Nonsmokers, n                           7                                                     14
   Smokers, n (pack years)                 16 (30.5±26.8)                                        22 (39.03±30.4)[a](#tfn1-copd-9-863){ref-type="table-fn"}
  Pulmonary function                                                                             
   FEV~1~, L                               1.59±0.84[a](#tfn1-copd-9-863){ref-type="table-fn"}   0.86±0.40[\*](#tfn2-copd-9-863){ref-type="table-fn"},[a](#tfn1-copd-9-863){ref-type="table-fn"}
   FEV~1~, %Ref                            91.79±12.53                                           35.39±13.64[\*](#tfn2-copd-9-863){ref-type="table-fn"},[a](#tfn1-copd-9-863){ref-type="table-fn"}
   FEV~1~/FVC, %                           75.62±3.81                                            40.04±8.31[\*](#tfn2-copd-9-863){ref-type="table-fn"}
   FVC, L                                  2.92±0.65                                             2.11±0.71[\*](#tfn2-copd-9-863){ref-type="table-fn"}
   FVC, %Ref                               91.85±12.24                                           67.41±20.92[\*](#tfn2-copd-9-863){ref-type="table-fn"}
  Length of remission, days                                                                      11.7±3.52
  Duration of disease, years                                                                     14.2±6.78
  Severity stage, n                                                                              
   I                                                                                             NA
   II                                                                                            4
   III                                                                                           16
   IV                                                                                            16
  Medication use, n                                                                              
   Antibiotics                                                                                   36
   Intravenous glucocorticoids                                                                   12
   Inhaled glucocorticoids and β-agonist                                                         34
   Anticholinergics                                                                              14
  With pulmonary heart disease, n                                                                17

**Notes:**

Data with skewed distribution were expressed as medians \[IQR\]

*P*\<0.001

*P*=0.021.

**Abbreviations:** AECOPD, acute exacerbation of chronic obstructive pulmonary disease; FVC, forced vital capacity; FEV~1~, forced expiratory volume in one second; IQR, interquartile range; Ref, reference value; NA, not applicable.

###### 

Results of blood analysis and biochemical indices

                              Controls (n=23)                                       AECOPD                                                                                            
  --------------------------- ----------------------------------------------------- ------------------------------------------------------------------------------------------------- -----------------------------------------------------
  Blood gas analysis                                                                                                                                                                  
   pO~2~, mmHg                79.9±6.2                                              74.5±19.3                                                                                         75.45±11.0
   pCO~2~, mmHg               39.1±1.4                                              55.2±9.8[\*](#tfn6-copd-9-863){ref-type="table-fn"},[a](#tfn5-copd-9-863){ref-type="table-fn"}    48.8±7.3
   pH                         7.39±0.02                                             7.39±0.05                                                                                         7.40±0.03
   HCO~3~, mmol/L             24.5±1.2                                              32.4±4.3[\*](#tfn6-copd-9-863){ref-type="table-fn"}                                               30.5±4.1
  Biochemistry                                                                                                                                                                        
   Protein, g/L               72.1±3.37[a](#tfn5-copd-9-863){ref-type="table-fn"}   64.4±8.08[\*](#tfn6-copd-9-863){ref-type="table-fn"},[a](#tfn5-copd-9-863){ref-type="table-fn"}   60.3±6.58
   Albumin, g/L               45.6±3.37                                             37.6±3.95[\*](#tfn6-copd-9-863){ref-type="table-fn"}                                              35.3±4.47
   Cholesterol, mmol/L        4.0±0.34                                              4.0±0.76                                                                                          3.8±0.81
   Glucose, mmol/L            5.2±0.50                                              5.6±0.86[†](#tfn7-copd-9-863){ref-type="table-fn"}                                                5.6±0.80
   Potassium, mmol/L          4.1±0.18                                              4.08±0.41                                                                                         4.0±0.43
   Sodium, mmol/L             138.3±1.81                                            141.6±4.76[\*](#tfn6-copd-9-863){ref-type="table-fn"}                                             142.1±5.5
  Routine analysis of blood                                                                                                                                                           
   Hemoglobin, g/L            139.8±12.2                                            129.6±14.3[‡](#tfn8-copd-9-863){ref-type="table-fn"}                                              130.6±16.3
   WBC ×10^9^/L               6.03±1.41                                             8.23±3.31[\*](#tfn6-copd-9-863){ref-type="table-fn"},[a](#tfn5-copd-9-863){ref-type="table-fn"}   7.56±2.14
   Neutrophils, %             50.7±17.0[a](#tfn5-copd-9-863){ref-type="table-fn"}   76.5±9.52[\*](#tfn6-copd-9-863){ref-type="table-fn"}                                              72.0±6.41
  Inflammatory markers                                                                                                                                                                
   CRP, mg/L                  6.0±2.71                                              33.5±9.54[\*](#tfn6-copd-9-863){ref-type="table-fn"},[a](#tfn5-copd-9-863){ref-type="table-fn"}   22.4±17.3[a](#tfn5-copd-9-863){ref-type="table-fn"}
   IL-6, pg/mL                5.4±2.73                                              14.6±7.2[\*](#tfn6-copd-9-863){ref-type="table-fn"},[a](#tfn5-copd-9-863){ref-type="table-fn"}    14.8±9.6[a](#tfn5-copd-9-863){ref-type="table-fn"}

**Notes:**

Data with skewed distribution were expressed as medians \[IQR\].

*P*\<0.001

*P*=0.023

*P*=0.00 for AECOPD versus controls.

**Abbreviations:** AECOPD, acute exacerbation of chronic obstructive pulmonary disease; CRP, C-reactive protein; WBC, white blood cells; IL-6, interleukin 6; pO~2~, pressure of oxygen; pCO~2~, pressure of carbon dioxide.
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